# Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

> **NCT02673138** · NA · COMPLETED · sponsor: **Yale University** · enrollment: 10 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** canagliflozin
- **OTHER:** basal interruption without canagliflozin

## Key facts

- **NCT ID:** NCT02673138
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673138, "Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02673138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*